EMCURE PHARMACEUTICALS LTD - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - US FDA Inspection At API Manufacturing Facility Located At Kurkumbh, Pune, Maharashtra, India

Emcure Pharmaceuticals Ltd - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - US FDA Inspection At API Manufacturing Facility Located At Kurkumbh, Pune, Maharashtra, India

Download	< Back
26 Feb 2025
Pursuant to Regulation 30 of the SEBI Listing Regulations, this is to inform you that the US FDA had conducted a cGMP inspection of the Company''s API manufacturing facility located at Kurkumbh, Pune, Maharashtra, India from February 19, 2025 to February 25, 2025. On conclusion of the inspection, the Company received two observations in Form 483.
View all announcements for Emcure Pharmaceuticals Ltd	Source: BSE India

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2025	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Advertise with us

ALL MONEYWIZ PAGES

Stocks

Mutual Funds

Investment tracking